[go: up one dir, main page]

PE20050336A1 - Compuestos triciclicos como inhibidores de la proteina farnesil transferasa - Google Patents

Compuestos triciclicos como inhibidores de la proteina farnesil transferasa

Info

Publication number
PE20050336A1
PE20050336A1 PE2004000760A PE2004000760A PE20050336A1 PE 20050336 A1 PE20050336 A1 PE 20050336A1 PE 2004000760 A PE2004000760 A PE 2004000760A PE 2004000760 A PE2004000760 A PE 2004000760A PE 20050336 A1 PE20050336 A1 PE 20050336A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
cycloalkyl
group
inhibitors
Prior art date
Application number
PE2004000760A
Other languages
English (en)
Inventor
Ronald J Doll
Alan B Cooper
James J-S Wang
Viyyoor M Girijavallabhan
F George Njoroge
Hugh Y Zhu
Dinanath F Rane
Jagdish A Desai
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34138747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050336(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20050336A1 publication Critical patent/PE20050336A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE LA FORMULA I, EN DONDE R1 ES UN GRUPO a ENTRE OTROS, DONDE n ES 1-6; X ES O, S o N; R2, R3, R4 Y R5 SON H, Br, Cl o F; R5A ES H, ALQUILO C1-C6 o CICLOALQUILO C3-C6; R6 Y R7 SON H, ALQUILO C1-C4 o CICLOALQUILO C3-C7, ENTRE OTROS; R8 SE SELECCIONA DEL GRUPO CONSISTENTE EN LOS RADICALES 2.0, 3.0, ENTRE OTROS; R9 ES ALQUILO C1-C6, ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS, CON LA CONDICION DE QUE EL ATOMO DE C, MEDIANTE EL CUAL DICHO GRUPO R9 ESTA UNIDO AL SUSTITUYENTE X, NO ESTA SUSTITUIDO CON UN GRUPO -OH, NH2, NH(ALQUILO C1-C6)2 o N(ALQUILO C1-C6)2; R10 ES ARILO, HETEROARILO, CICLOALQUILO, HETEROCICLOALQUILO, ENTRE OTROS; R11 ES ALQUILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER ISOPROPILICO DEL ACIDO 4-{8-CLORO-6-[[(1-METOXI-CICLOPROPANOCARBONIL)-AMINO]-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-11H-BENZO[5,6]CICLOHEPTA[1,2-b]PIRIDIN-11-IL-PIPERAZIN}-1-CARBOXILICO; ESTER ISOPROPILICO DEL ACIDO 4-{8-CLORO-6-[[(1-HIDROXI-CICLOPROPANOCARBONIL)-AMINO]-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-11H-BENZO[5,6]CICLOHEPTA[1,2-b]PIRIDIN-11-IL-PIPERAZIN}-1-CARBOXILICO; ESTER CICLOPENTILICO DEL ACIDO 4-{6-[(BICICLOPROPIL-1-ILOXICARBONILAMINO)-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-8-CLORO-11H-BENZO[5,6]CICLOHEPTA[1,2-b]PIRIDIN-11-IL}-PIPERAZIN-1-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN KIT Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA FARNESILO TRANSFERASA Y SON UTILES EN EL TRATAMIENTO DE TUMORES
PE2004000760A 2003-08-07 2004-08-05 Compuestos triciclicos como inhibidores de la proteina farnesil transferasa PE20050336A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49326903P 2003-08-07 2003-08-07
US49850903P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
PE20050336A1 true PE20050336A1 (es) 2005-05-30

Family

ID=34138747

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000760A PE20050336A1 (es) 2003-08-07 2004-08-05 Compuestos triciclicos como inhibidores de la proteina farnesil transferasa

Country Status (18)

Country Link
US (1) US7557107B2 (es)
EP (1) EP1660477B1 (es)
JP (1) JP2007501791A (es)
KR (1) KR20060057599A (es)
AR (1) AR045447A1 (es)
AT (1) ATE417041T1 (es)
AU (1) AU2004263493A1 (es)
BR (1) BRPI0413384A (es)
CA (1) CA2535210A1 (es)
DE (1) DE602004018332D1 (es)
EC (1) ECSP066349A (es)
ES (1) ES2317047T3 (es)
IL (1) IL173514A0 (es)
MX (1) MXPA06001483A (es)
PE (1) PE20050336A1 (es)
RU (1) RU2006106768A (es)
TW (1) TW200510384A (es)
WO (1) WO2005014577A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US20040082588A1 (en) * 2002-09-30 2004-04-29 Schering Corporation Methods for treating disorders of calcium homeostasis
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
EP1831200A2 (en) * 2004-12-21 2007-09-12 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
EP1854465A1 (en) 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
CA2683109A1 (en) * 2006-10-11 2008-04-17 Fusion Antibodies Limited Combination therapy
MX2010004450A (es) 2007-10-22 2010-05-05 Schering Corp Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
PL185597B1 (pl) * 1995-12-22 2003-06-30 Schering Corp Tricykliczne amidy, środek farmaceutyczny i ich zastosowania
JP2003525239A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
US20030229099A1 (en) 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20040082588A1 (en) * 2002-09-30 2004-04-29 Schering Corporation Methods for treating disorders of calcium homeostasis
EP1831200A2 (en) 2004-12-21 2007-09-12 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents

Also Published As

Publication number Publication date
CA2535210A1 (en) 2005-02-17
DE602004018332D1 (de) 2009-01-22
EP1660477B1 (en) 2008-12-10
HK1087122A1 (en) 2006-10-06
AU2004263493A1 (en) 2005-02-17
ATE417041T1 (de) 2008-12-15
US7557107B2 (en) 2009-07-07
ES2317047T3 (es) 2009-04-16
WO2005014577A1 (en) 2005-02-17
ECSP066349A (es) 2006-08-30
JP2007501791A (ja) 2007-02-01
BRPI0413384A (pt) 2006-10-17
AR045447A1 (es) 2005-10-26
RU2006106768A (ru) 2007-09-20
WO2005014577A9 (en) 2006-03-23
US20050059672A1 (en) 2005-03-17
TW200510384A (en) 2005-03-16
EP1660477A1 (en) 2006-05-31
MXPA06001483A (es) 2006-05-15
KR20060057599A (ko) 2006-05-26
IL173514A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
PE20050336A1 (es) Compuestos triciclicos como inhibidores de la proteina farnesil transferasa
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
PE20091095A1 (es) Moduladores de gamma secretasa
PE20020406A1 (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS 2,6-DISUSTITUIDAS COMO INHIBIDORES DE LAS PROTEINAS CINASAS
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
PE20060570A1 (es) Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20040450A1 (es) Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
AR040349A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης

Legal Events

Date Code Title Description
FC Refusal